Gastrointestinal Sendrom ve Medikal Terapotik Yaklaşım
Özet
Akut Radyasyon Sendromu'nun (ARS) en kritik bileşenlerinden biri olan gastrointestinal (Gİ) sendrom, özellikle abdominal ve pelvik bölgeye uygulanan yüksek dozda iyonize radyasyon tedavisi sonrasında ya da radyasyon kazalarında ortaya çıkan, yüksek mortalite ve morbidite riskine sahip ciddi bir klinik tablodur. Patogenezinde, intestinal kriptlerde yer alan ve radyasyona oldukça duyarlı olan immatür parankimal kök hücrelerin hasar görmesi ile mukoza bütünlüğünün bozulması ve mikrotrombüs gelişimine yol açan endotelyal apoptozis temel rol oynar. Bariyer bütünlüğünün kaybolması; sıvı-elektrolit kaybına, şiddetli kanlı diyareye ve bağırsak florasındaki bakterilerin sistemik dolaşıma geçerek ölümcül sepsis ile çoklu organ yetmezliğine yol açmasına neden olur. Klinik seyir alınan doza bağlı olarak akut (radyoterapiden sonraki ilk 90 gün) veya transmural fibrozis ile vasküler sklerozun eşlik ettiği kronik (90 gün sonrası) semptomlarla kendini gösterir. Tedavi yaklaşımı; onkolog, gastroenterolog ve enfeksiyon uzmanından oluşan multidisipliner bir ekip tarafından yönetilmeli; kinolon bazlı ampirik antibiyotik tedavisini, mukoza hasarını azaltmaya yönelik büyüme faktörlerini (KGF, palifermin) ve hastanın immün sistemini desteklemek adına erken dönemde başlanan enteral nutrisyon desteğini içermelidir.
Gastrointestinal (GI) syndrome, a critical component of Acute Radiation Syndrome (ARS), is a severe clinical condition characterized by high mortality and morbidity risks, occurring primarily after high-dose ionizing radiation therapy for abdominal or pelvic malignancies, or in radiation accidents. In its pathogenesis, the inhibition of mitotic activity and subsequent apoptosis of highly radiosensitive immature parenchymal stem cells within intestinal crypts, alongside endothelial injury, play the key roles in compromising mucosal barrier integrity. The disruption of this intestinal barrier leads to profound fluid-electrolyte loss, severe bloody diarrhea, and increased permeability to luminal bacteria, which triggers systemic infections, fatal septicemia, and multi-organ dysfunction syndrome. The clinical manifestations are highly dose-dependent, presenting as either reversible acute symptoms (up to 90 days post-exposure) or irreversible chronic complications driven by progressive transmural fibrosis and vascular sclerosis. Management of GI radiation injury demands a multidisciplinary approach involving oncologists, gastroenterologists, and infectious disease specialists, focusing on empirical antibiotic prophylaxis with quinolones to prevent sepsis, administration of mucosal healing growth factors like palifermin, and early initiation of tailored enteral nutrition support to maintain an anabolic state.
Referanslar
Bethesda, (2001) National Council on Radiation Protection and Measurements. Management of terrorist events involving radioactive material. NCRP report No 138.
López M, Martín M. Medical management of the acute radiation syndrome. Rep Pract Oncol Radiother, 2011;16(4):138-46.
Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med, 2004;140:1037–1051.
Ho AY, Atencio DP, Peters S, et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys, 2006;65:646–655.
Coeytaux K, Bey E, Christensen D, Glassman ES, Murdock B, Doucet C. Reported radiation overexposure accidents worldwide, 1980-2013: a systematic review. PLoS One, 2015;10(3):e0118709.
Paris F, Fuks Z, Kang A, et al. Capodieci P, Juan G, Ehleiter D, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293(5528):293-7.
Shadad AK, Sullivan FJ, Martin JD, Egan LJ. Gastrointestinal radiation injury: Symptoms, risk factors and mechanisms. World J Gastroenterol, 2013;19(2):185-198.
Elliott TB, Deutz NE, Gulani J, et al. Gastrointestinal Acute Radiation Syndrome in Göttingen Minipigs (Sus Scrofa Domestica). Comparative Medicine, 2014;64(6):456-463.
Kirsch DG, Santiago PM, Tomasso E, et al. p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosisp53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis. Science. 2010;327(5965):593-6.
Fernandes A, Oliveira A, Soares R, Barata P. The Effects of Ionizing Radiation on Gut Microbiota, a Systematic Review. Nutrients, 2021;13(9):3025.
Berger ME, Christensen DM, Lowry PC, Jones OW, Wiley AL. Medical management of radiation injuries: current approaches. Occupational Medicine, 2006;56:162–172.
Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut, 20015;54:1051-1054.
Guskova AK, Nadezhina NM, Moiseev AA et al. Medical assistance given to personnel of the Chernobyl nuclear power plant after the 1986 accident. Hematol Rev, 1996;7:27–100.
Nagayama H, Ooi J, Tomonari A et al. Severe immune dysfunction after lethal neutron irradiation in a JCO nuclear facility accident victim. Int J Hematol, 2002;76(2):157–64.
Stokman MA, Spijkervet FK, Burlage FR et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomized clinical trial. Br J Cancer, 2003;88:1012–16.
Sprinzl GM, Galvan O, deVries A et al. Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer, 2001;37:2003-9.
Spielberger R, Stiff P, Bensinger Wet al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med, 2004;351:2590–98.
Otterson MF, Sarna SK, Moulder JE. Effects of fractionated doses of ionizing radiation on small intestinal motor activity. Gastroenterology. 1988;95:1249–1257.
Potten CS. Radiation injury of the gastrointestinal epithelium: current research on treatment, management, and prevention. In: Ricks RC, Berger ME, O’Hara FM, eds. The Medical Basis for Radiation—Accident Preparedness: The Clinical Care of Victims. New York: Parthenon, 2002;139–148.
